SEC Tracker
Get the app
AIM · XBRL financial data

AIM ImmunoTech financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (AIM's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue4665*40503545*16252621*2226
Revenue from contracts with customers4665*40503545*16252621*2226
Research and development2,7343,200*1,9511,1451,4371,664*1,0801,1746071,063*482589
General and administrative5,43910,857*3,8152,5913,0794,229*2,5451,4871,7981,870*1,7622,945
Operating income (loss)(8,157)(14,004)*(5,734)(3,694)(4,489)(5,855)*(3,619)(2,646)(2,447)(2,952)*(2,226)(3,513)
Interest expense——72179202132*124149148391*304295
Other income (expense)294258*812,5807181,813*1110—year only821
Net income (loss)(7,816)(12,576)*(5,817)(1,836)(3,700)(5,967)*(3,705)(2,794)(3,284)(4,175)*(3,023)(3,788)
Earnings per share, basic USD per share(0.16)—(0.12)(0.03)(0.06)(0.09)*(0.05)(3.68)1.57—(0.69)(0.43)
Earnings per share, diluted USD per share(0.16)(0.26)*(0.12)(0.03)(0.06)(0.09)*(0.05)(3.68)1.57—(0.69)(0.43)
Weighted average shares, basic thousands of shares48,63548,889*49,45852,83757,67763,989*70,3307592,093—4,35117,119
Weighted average shares, diluted thousands of shares48,63548,889*49,45852,83757,67763,989*70,3307592,093—4,35117,119
  • † Share count changed about 1/28 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (AIM's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents15,2645,4393,2953,5549151,7018984762,3472,9855,8169,900
Short-term investments7,1677,6317,6476,507————————
Marketable securities7,1677,6317,6476,5076,2872,2761,34935962626364
Accounts receivable481,184———————7——
Prepaid and other current assets263302364300368199318190166241335468
Total current assets22,74214,55611,30610,3617,5704,1762,5841,0252,5753,2956,21410,432
Property and equipment, net136127118109117108988980716254
Right-of-use asset727697763700653618554496436378320260
Total assets27,86119,38116,18915,71513,5888,6086,2484,1295,4945,7828,58512,731
Accounts payable2,7886,4436,5675,4556,2646,3836,9447,2971,2521,6301,215480
Accrued liabilities1,7211,9861,4467991,011606639573679795671586
Current portion of long-term debt——1,6232,3542,5932,3071,9502,2901,8803,5494,0043,621
Total current liabilities4,7168,6529,8768,84210,1009,5359,76710,3934,0436,2246,1454,946
Long-term debt——950283139————927210—
Lease liability, non-current54349553748843739533828222617010541
Total liabilities—9,14711,3639,61310,6769,93010,10510,67511,57115,5656,4604,987
Accumulated deficit(396,932)(409,508)(415,325)(417,161)(420,861)(426,828)(430,533)(433,327)(436,611)(440,786)(443,809)(447,597)
Total stockholders' equity22,60210,2344,8266,1022,912(1,322)(3,857)(6,546)(6,077)(9,783)2,1257,744
Total liabilities and equity27,86119,38116,18915,71513,5888,6086,2484,1295,4945,7828,58512,731
Common shares outstanding (cover page) thousands of shares48,84249,90151,28157,13763,70672,29076,4242,7092,8538,14814,56430,442
  • † Share count changed about 1/28 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (AIM's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(7,816)(12,576)*(5,817)(1,836)(3,700)(5,967)*(3,705)(2,794)(3,284)(4,175)*(3,023)(3,788)
Stock-based compensation5061*808080196*600*0*0*——
Net cash from operating activities(5,671)*(9,758)*(4,815)(3,008)*(3,110)*(3,955)*(2,361)(1,531)*(5,079)*(1,986)*(2,719)(4,590)*
Purchases of property and equipment—————0*——————
Net cash from investing activities(336)*(214)*(158)826*334*3,704*898754*296*(95)*(37)(112)*
Proceeds from issuing common stock——————660105*——2,001537*
Proceeds from issuing equity233*147*329527*4*32*660105*(398)*———
Net cash from financing activities233*147*2,8292,441*137*1,037*660355*6,654*2,719*5,5878,786*
Net change in cash(5,774)*(9,825)*(2,144)259*(2,639)*786*(803)(422)*1,871*638*2,8314,084*
  • † Share count changed about 1/28 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
AIM ImmunoTech9,90026(4,590)*30.4M2.2 quarters 10-QJun 30, 2026
Vyome Holdings7,88827(904)*7.0M8.7 quarters 10-QJun 30, 2026
America Great Health29261.7*21.2B— 10-QMar 31, 2026
Adial Pharmaceuticals28,712not reported(6,363)*2.6M4.5 quarters 10-Q/AJun 30, 2026
PharmaCyte Biotech17,7390(781)10.7M22.8 quarters 10-QJul 31, 2026
Natural Alternatives International7,388not reported(1,066)*22.1M6.9 quarters 10-KJun 30, 2026
LFTD Partners1,5048,705(555)*14.8M2.7 quarters 10-QJun 30, 2026
Biomerica2,7331,265(802)4.6M3.4 quarters 10-QAug 31, 2026
Protagenic Therapeutics, Inc.\new566not reported(944)1.8M0.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.